DNA — Ginkgo Bioworks Holdings, Inc.

Summary of DNA (Ginkgo Bioworks) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cell Engineering Revenue: $26 million in Q4 2025, down 26% year-over-year. Full-year revenue was $133 million, down from $174 million in 2024.
• Biosecurity Revenue: $7 million in Q4 2025, totaling $37 million for the full year.
• Adjusted EBITDA: Q4 2025 was negative $36 million, improved from negative $57 million in Q4 2024. Full-year adjusted EBITDA was negative $167 million, down from negative $293 million in 2024.
• Cash Burn: Q4 2025 cash burn was $47 million, down from $55 million in Q4 2024. Full-year cash burn decreased by 55% to $171 million from $383 million in 2024.

2. Strategic Updates and Business Highlights

• Focus on Autonomous Labs: The company is pivoting to invest heavily in autonomous labs, which integrate robotics and AI to enhance laboratory efficiency. Plans include decommissioning traditional lab setups in favor of a centralized autonomous lab in Boston.
• Divestiture of Biosecurity Business: Ginkgo announced plans to divest its Biosecurity business to focus resources on autonomous labs, while still retaining a minority interest in the spun-off entity.
• Partnerships and Contracts: Notable contracts include a $47 million deal with Pacific Northwest National Labs for the development of a 97-robot autonomous lab. The company is also collaborating with OpenAI to integrate AI into lab processes.
• Operational Efficiency: Significant reductions in R&D and G&A expenses due to restructuring efforts, leading to improved financial metrics.

3. Forward Guidance and Outlook

• 2026 Cash Burn Guidance: Expected to be between $125 million and $150 million, reflecting a balance between cost efficiency and investment in autonomous labs.
• Revenue Guidance: No specific revenue guidance provided for 2026, with a focus on cash burn as a more relevant metric for ongoing operations and investments.

4. Bad News, Challenges, or Points of Concern

• Declining Revenue: Both Cell Engineering and Biosecurity revenues have seen significant declines, raising concerns about the sustainability of current business models.
• Market Conditions: The biotech sector is experiencing a downturn, impacting customer spending on outsourced R&D projects.
• Operational Risks: Transitioning to autonomous labs involves technical challenges and the need for substantial investment, which could pose risks if market adoption is slower than anticipated.

5. Notable Q&A Insights

• Utilization of RACs: Expansion of RACs from 50 to 100 units is aimed at increasing capacity for research services, with a mix of recurring revenue expected from software and consumables.
• Onshoring Manufacturing: There is potential for growth in RACs revenue due to U.S. onshoring of manufacturing, particularly in quality control applications.
• Datapoints Offering: The Datapoints service is gaining traction, with increasing demand for large data sets necessary for training bio AI models, positioning Ginkgo as a leader in this niche.

Overall, Ginkgo Bioworks is navigating a challenging biotech landscape while strategically pivoting towards autonomous labs, which it believes will define its future growth. However, declining revenues and the need for significant investment in new technologies present ongoing risks.